AKT1 and ovarian carcinoma: ITGAX is closely associated with tumor development, and ITGAX promotes c-Myc-mediated VEGF-A transcription by activating the PI3K/Akt pathway and binding to VEGFR2 on the cell membrane, enhancing angiogenesis during ovarian cancer growth [27].